Hermann Sorgho

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7944922/publications.pdf

Version: 2024-02-01

41 papers 3,628 citations

331670
21
h-index

265206 42 g-index

42 all docs 42 docs citations

42 times ranked 4798 citing authors

#	Article	IF	CITATIONS
1	First Results of Phase 3 Trial of RTS,S/ASO1 Malaria Vaccine in African Children. New England Journal of Medicine, 2011, 365, 1863-1875.	27.0	773
2	A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. New England Journal of Medicine, 2012, 367, 2284-2295.	27.0	653
3	Enabling the genomic revolution in Africa. Science, 2014, 344, 1346-1348.	12.6	361
4	Genetic Diversity and Protective Efficacy of the RTS,S/ASO1 Malaria Vaccine. New England Journal of Medicine, 2015, 373, 2025-2037.	27.0	332
5	Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2015, 15, 1450-1458.	9.1	262
6	Concentration and avidity of antibodies to different circumsporozoite epitopes correlate with RTS,S/AS01E malaria vaccine efficacy. Nature Communications, 2019, 10, 2174.	12.8	123
7	Regional and Sex Differences in the Prevalence and Awareness of Hypertension: An H3Africa AWI-Gen Study Across 6 Sites in Sub-Saharan Africa. Global Heart, 2017, 12, 81.	2.3	105
8	Genomic and environmental risk factors for cardiometabolic diseases in Africa: methods used for Phase 1 of the AWI-Gen population cross-sectional study. Global Health Action, 2018, 11, 1507133.	1.9	82
9	Major reduction of malaria morbidity with combined vitamin A and zinc supplementation in young children in Burkina Faso: a randomized double blind trial. Nutrition Journal, 2008, 7, 7.	3.4	81
10	Profile: Nanoro Health and Demographic Surveillance System. International Journal of Epidemiology, 2012, 41, 1293-1301.	1.9	79
11	An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malaria Journal, 2012, 11, 71.	2.3	74
12	Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/ASO1E vaccination in African children. BMC Medicine, 2018, 16, 197.	5. 5	65
13	Kidney damage and associated risk factors in rural and urban sub-Saharan Africa (AWI-Gen): a cross-sectional population study. The Lancet Global Health, 2019, 7, e1632-e1643.	6.3	56
14	Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Human Vaccines and Immunotherapeutics, 2019, 15, 2386-2398.	3.3	48
15	Long-term incidence of severe malaria following RTS,S/ASO1 vaccination in children and infants in Africa: an open-label 3-year extension study of a phase 3 randomised controlled trial. Lancet Infectious Diseases, The, 2019, 19, 821-832.	9.1	45
16	Serodiagnosis of Schistosoma mansoni infections in an endemic area of Burkina Faso: performance of several immunological tests with different parasite antigens. Acta Tropica, 2005, 93, 169-180.	2.0	37
17	Regional and sex-specific variation in BMI distribution in four sub-Saharan African countries: The H3Africa AWI-Gen study. Global Health Action, 2018, 11, 1556561.	1.9	37
18	Artesunate-Amodiaquine and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PLoS ONE, 2016, 11, e0151565.	2.5	37

#	Article	IF	CITATIONS
19	Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections. Nature Communications, 2018, 9, 1381.	12.8	27
20	Effectiveness of artesunate–amodiaquine <i>>vs</i> . artemether–lumefantrine for the treatment of uncomplicated <i>falciparum</i> malaria in Nanoro, Burkina Faso: a nonâ€inferiority randomised trial. Tropical Medicine and International Health, 2014, 19, 469-475.	2.3	24
21	Diagnosing congenital malaria in a high-transmission setting: clinical relevance and usefulness of P. falciparum HRP2-based testing. Scientific Reports, 2017, 7, 2080.	3.3	24
22	Modulation of innate immune responses at birth by prenatal malaria exposure and association with malaria risk during the first year of life. BMC Medicine, 2018 , 16 , 198 .	5 . 5	24
23	Ex vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy change. Malaria Journal, 2014, 13, 207.	2.3	22
24	Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial. Malaria Journal, 2015, 14, 325.	2.3	22
25	Malaria incidence and prevalence during the first year of life in Nanoro, Burkina Faso: a birth-cohort study. Malaria Journal, 2018, 17, 163.	2.3	21
26	Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. Reproductive Health, 2015, 12, 112.	3.1	20
27	The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso. Malaria Journal, 2014, 13, 113.	2.3	19
28	Meta-analysis of sub-Saharan African studies provides insights into genetic architecture of lipid traits. Nature Communications, 2022, 13, 2578.	12.8	18
29	In vivo/ex vivo efficacy of artemether–lumefantrine and artesunate–amodiaquine as first-line treatment for uncomplicated falciparum malaria in children: an open label randomized controlled trial in Burkina Faso. Malaria Journal, 2020, 19, 8.	2.3	17
30	Community perspectives on maternal and child health during nutrition and economic transition in sub-Saharan Africa. Public Health Nutrition, 2021, 24, 3710-3718.	2.2	17
31	Prevalence and socio-demographic correlates of tobacco and alcohol use in four sub-Saharan African countries: a cross-sectional study of middle-aged adults. BMC Public Health, 2021, 21, 1126.	2.9	16
32	The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: a random sampling survey. BMC Infectious Diseases, 2020, 20, 46.	2.9	15
33	Immune response to the hepatitis B antigen in the RTS,S/AS01 malaria vaccine, and co-administration with pneumococcal conjugate and rotavirus vaccines in African children: A randomized controlled trial. Human Vaccines and Immunotherapeutics, 2018, 14, 1489-1500.	3.3	14
34	Safety and immunogenicity of the RTS,S/ASO1 malaria vaccine in infants and children identified as HIV-infected during a randomized trial in sub-Saharan Africa. Vaccine, 2020, 38, 897-906.	3.8	12
35	Dynamic of plasmodium falciparum chloroquine resistance transporter gene Pfcrt K76T mutation five years after withdrawal of chloroquine in Burkina Faso. Pan African Medical Journal, 2015, 21, 101.	0.8	11
36	Novel and Known Gene-Smoking Interactions With cIMT Identified as Potential Drivers for Atherosclerosis Risk in West-African Populations of the AWI-Gen Study. Frontiers in Genetics, 2019, 10, 1354.	2.3	10

#	Article	IF	CITATIONS
37	Genetic associations with carotid intima-media thickness link to atherosclerosis with sex-specific effects in sub-Saharan Africans. Nature Communications, 2022, 13, 855.	12.8	10
38	â€~Men are not playing their roles', maternal and child nutrition in Nanoro, Burkina Faso. Public Health Nutrition, 2020, 24, 1-11.	2.2	9
39	Gender differences in sociodemographic and behavioural factors associated with BMI in an adult population in rural Burkina Faso – an AWI-Gen sub-study. Global Health Action, 2018, 11, 1527557.	1.9	8
40	<p>Optimal Approach and Strategies to Strengthen Pharmacovigilance in Sub-Saharan Africa: A Cohort Study of Patients Treated with First-Line Artemisinin-Based Combination Therapies in the Nanoro Health and Demographic Surveillance System, Burkina Faso</p> . Drug Design, Development and Therapy, 2020, Volume 14, 1507-1521.	4.3	8
41	Strong off-target antibody reactivity to malarial antigens induced by RTS,S/AS01E vaccination is associated with protection. JCI Insight, 2022, 7, .	5.0	6